D-secopaclitaxel | 135393-42-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: D-secopaclitaxel
• 英文别名: 20-acetoxy-4-deacetyl-5-epi-20,O-secotaxol；[(1S,2S,3R,4S,5S,7S,8S,10R,13S)-10-acetyloxy-4-(acetyloxymethyl)-13-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,4,5,7-tetrahydroxy-8,12,15,15-tetramethyl-9-oxo-2-tricyclo[9.3.1.03,8]pentadec-11-enyl] benzoate
• CAS: 135393-42-9
• 化学式: C₄₇H₅₃NO₁₅
• 分子量: 871.936
• InChiKey: IQYMRGIQFZZVCP-SJBOGKINSA-N

物化性质

• 沸点：
  984.2±65.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  63
• 可旋转键数：
  15
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  253
• 氢给体数：
  6
• 氢受体数：
  15

反应信息

• 作为产物：
  描述：

  紫杉醇 在 triethyloxonium fluoroborate 作用下， 生成 D-secopaclitaxel
  参考文献：
  名称：

  [EN] ANTIBODY-NANOPARTICLE COMPLEXES AND METHODS FOR MAKING AND USING THE SAME
  [FR] COMPLEXES ANTICORPS-NANOPARTICULES ET LEURS PROCÉDÉS DE FABRICATION ET MÉTHODES D'UTILISATION

  摘要：

  Provided herein are nanoparticles complexed with binding agents and/or therapeutic agents (e.g., antibody-complexed albumin-bound paclitaxel/doxorubicin nanoparticles and antibody-complexed albumin-bound paclitaxel/SN38 nanoparticles) and pharmaceutical compositions thereof. Additionally, provided herein are methods of making nanoparticles complexed with binding agents and/or therapeutic agents (e.g., antibody-complexed albumin-bound paclitaxel/doxorubicin nanoparticles and antibody-complexed albumin-bound paclitaxel/SN38 nanoparticles) and methods of treating cancer in a patient in need thereof.

  公开号：

  WO2022051414A1

文献信息

• [EN] ANTIBODY-NANOPARTICLE COMPLEXES AND METHODS FOR MAKING AND USING THE SAME<br/>[FR] COMPLEXES ANTICORPS-NANOPARTICULES ET LEURS PROCÉDÉS DE FABRICATION ET MÉTHODES D'UTILISATION
  申请人：MAYO FOUND MEDICAL EDUCATION & RES

  公开号：WO2022051414A1

  公开（公告）日：2022-03-10

  Provided herein are nanoparticles complexed with binding agents and/or therapeutic agents (e.g., antibody-complexed albumin-bound paclitaxel/doxorubicin nanoparticles and antibody-complexed albumin-bound paclitaxel/SN38 nanoparticles) and pharmaceutical compositions thereof. Additionally, provided herein are methods of making nanoparticles complexed with binding agents and/or therapeutic agents (e.g., antibody-complexed albumin-bound paclitaxel/doxorubicin nanoparticles and antibody-complexed albumin-bound paclitaxel/SN38 nanoparticles) and methods of treating cancer in a patient in need thereof.